Bio2 Technologies Enrolls First Vitrium Patient in Cervical Spine Fusion Trial

Bio2 Technologies enrolled the first patient in the randomized, multi-center, non-inferiority Investigational Device Exemption clinical trial of the Vitrium cervical interbody device. The 168-patient study will compare Vitrium to allograft in spinal fusion.

The company received FDA approval for the trial in 4Q18 after pre-clinical studies...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us